These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20576111)

  • 1. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.
    Coffie PA; Tonwe-Gold B; Tanon AK; Amani-Bosse C; Bédikou G; Abrams EJ; Dabis F; Ekouevi DK
    BMC Infect Dis; 2010 Jun; 10():188. PubMed ID: 20576111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Côte d'Ivoire.
    Ekouevi DK; Coffie PA; Chaix ML; Tonwe-Gold B; Amani-Bosse C; Leroy V; Abrams EJ; Dabis F
    J Int AIDS Soc; 2010 Aug; 13():28. PubMed ID: 20678207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
    Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ
    AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
    Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
    HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
    Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
    HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
    Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.
    Aaron E; Kempf MC; Criniti S; Tedaldi E; Gracely E; Warriner A; Kumar R; Bachmann LH
    PLoS One; 2010 Sep; 5(9):e12617. PubMed ID: 20838641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.
    Peters PJ; Polle N; Zeh C; Masaba R; Borkowf CB; Oyaro B; Omolo P; Ogindo P; Ndivo R; Angira F; Lando R; Fowler MG; Weidle PJ; Thomas TK
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):142-9. PubMed ID: 22020069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
    Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
    PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
    Ouyang DW; Brogly SB; Lu M; Shapiro DE; Hershow RC; French AL; Leighty RM; Thompson B; Tuomala RE
    AIDS; 2010 Jan; 24(1):109-14. PubMed ID: 19926957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.
    Dong BJ; Zheng Y; Hughes MD; Frymoyer A; Verotta D; Lizak P; Sawe F; Currier JS; Lockman S; Aweeka FT;
    AIDS; 2012 Apr; 26(7):833-41. PubMed ID: 22301417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire.
    Seyler C; Anglaret X; Dakoury-Dogbo N; Messou E; Touré S; Danel C; Diakité N; Daudié A; Inwoley A; Maurice C; Tonwe-Gold B; Rouet F; N'Dri-Yoman T; Salamon R;
    Antivir Ther; 2003 Oct; 8(5):385-93. PubMed ID: 14640385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
    Andreotti M; Pirillo MF; Liotta G; Jere H; Maulidi M; Sagno JB; Luhanga R; Amici R; Mancini MG; Gennaro E; Marazzi MC; Vella S; Giuliano M; Palombi L; Mancinelli S
    BMC Infect Dis; 2014 Apr; 14():180. PubMed ID: 24708626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    ; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
    AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
    van Leth F; Andrews S; Grinsztejn B; Wilkins E; Lazanas MK; Lange JM; Montaner J;
    AIDS; 2005 Mar; 19(5):463-71. PubMed ID: 15764851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings.
    Kiertiburanakul S; Sungkanuparph S; Charoenyingwattana A; Mahasirimongkol S; Sura T; Chantratita W
    Curr HIV Res; 2008 Jan; 6(1):65-9. PubMed ID: 18288977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
    Jamisse L; Balkus J; Hitti J; Gloyd S; Manuel R; Osman N; Djedje M; Farquhar C
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):371-6. PubMed ID: 17259905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
    Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants.
    Toure S; Kouadio B; Seyler C; Traore M; Dakoury-Dogbo N; Duvignac J; Diakite N; Karcher S; Grundmann C; Marlink R; Dabis F; Anglaret X;
    AIDS; 2008 Apr; 22(7):873-82. PubMed ID: 18427206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.